ASCENTAGE PHARMA GROUP INTERNATIONAL Financials Ascentage Pharma Group International
Equities
6855
KYG0519B1023
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.62 HKD | +1.85% |
|
+12.23% | -35.46% |
| Apr. 25 | Ascentage Pharma to Present Four Studies at US Oncology Meet | MT |
| Apr. 09 | Ascentage Pharma Chairman Boosts Stake in Firm | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,459 | 7,154 | 5,919 | 5,861 | 7,064 | 4,642 | - | - |
| Enterprise Value (EV) 1 | 5,459 | 7,154 | 5,919 | 5,861 | 7,064 | 4,642 | 4,642 | 4,642 |
| P/E ratio | -3.78 x | -10.3 x | -7.48 x | -6.78 x | -7.56 x | -5.69 x | -7.5 x | -7.98 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 376 x | 575 x | 212 x | 27.9 x | 31.8 x | 15.5 x | 8.78 x | 7.89 x |
| EV / Revenue | 376 x | 575 x | 212 x | 27.9 x | 31.8 x | 15.5 x | 8.78 x | 7.89 x |
| EV / EBITDA | -10.2 x | -11.7 x | -7.92 x | -7.64 x | -9.4 x | -6.25 x | -7.59 x | -9.31 x |
| EV / FCF | -10.2 x | - | -5.63 x | -6.84 x | - | -6.91 x | -7.96 x | - |
| FCF Yield | -9.85% | - | -17.7% | -14.6% | - | -14.5% | -12.6% | - |
| Price to Book | - | 8.45 x | 4.74 x | 14.7 x | - | - | - | - |
| Nbr of stocks (in thousands) | 203,627 | 220,767 | 257,606 | 258,216 | 284,672 | 284,587 | - | - |
| Reference price 2 | 26.81 | 32.40 | 22.98 | 22.70 | 24.81 | 16.31 | 16.31 | 16.31 |
| Announcement Date | 3/29/20 | 3/31/21 | 3/21/22 | 3/22/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.51 | 12.45 | 27.91 | 209.7 | 222 | 299.9 | 528.4 | 588.5 |
| EBITDA 1 | -537.6 | -611.7 | -747.1 | -767 | -751.1 | -742.6 | -611.3 | -498.6 |
| EBIT 1 | -564 | -639.2 | -846.7 | -835.9 | -835.5 | -768.5 | -632.9 | -529.2 |
| Operating Margin | -3,886.12% | -5,133.85% | -3,033.72% | -398.58% | -376.38% | -256.25% | -119.76% | -89.93% |
| Earnings before Tax (EBT) 1 | -1,482 | -675.4 | -832.2 | -887.2 | -932.9 | -834.3 | -675.7 | -595 |
| Net income 1 | -1,481 | -677.6 | -782.4 | -882.9 | -925.6 | -809.3 | -619.8 | -577.1 |
| Net margin | -10,202.67% | -5,442.62% | -2,803.38% | -421.02% | -416.98% | -269.84% | -117.29% | -98.08% |
| EPS 2 | -7.088 | -3.140 | -3.070 | -3.350 | -3.280 | -2.867 | -2.175 | -2.044 |
| Free Cash Flow 1 | -537.8 | - | -1,050 | -857.2 | - | -672 | -583 | - |
| FCF margin | -3,705.37% | - | -3,763.66% | -408.75% | - | -224.07% | -110.33% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/29/20 | 3/31/21 | 3/21/22 | 3/22/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 | 2023 S2 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | - | - |
| Net margin | - | - |
| EPS 1 | -1.470 | -1.810 |
| Dividend per Share | - | - |
| Announcement Date | 8/21/23 | 3/27/24 |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -538 | - | -1,050 | -857 | - | -672 | -583 | - |
| ROE (net income / shareholders' equity) | - | -78% | -75.2% | -107% | - | -68% | -119% | - |
| ROA (Net income/ Total Assets) | -52.9% | -46.2% | -33.5% | -30.6% | - | - | - | - |
| Assets 1 | 2,799 | 1,468 | 2,336 | 2,885 | - | - | - | - |
| Book Value Per Share | - | 3.830 | 4.850 | 1.540 | - | - | - | - |
| Cash Flow per Share | - | - | - | -2.480 | - | - | - | - |
| Capex 1 | 77.5 | 250 | 435 | 235 | - | 10 | 10 | - |
| Capex / Sales | 533.7% | 2,007.4% | 1,560.07% | 111.87% | - | 3.33% | 1.89% | - |
| Announcement Date | 3/29/20 | 3/31/21 | 3/21/22 | 3/22/23 | 3/27/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.31
CNY
Average target price
27.24
CNY
Spread / Average Target
+67.01%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.46% | 641M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6855 Stock
- Financials Ascentage Pharma Group International
